Literature DB >> 21723047

Tyrosine kinase receptor RON and its ligand MSP in Merkel cell carcinoma.

Junji Nagahama1, Tsutomu Daa, Naomi Yada, Kenji Kashima, Sakuhei Fujiwara, Tetsunori Saikawa, Shigeo Yokoyama.   

Abstract

The RON gene, encoding the tyrosine-kinase receptor for macrophage-stimulating protein (MSP), is involved in a range of neoplastic processes. However, no aberration in RON or MSP has been identified in Merkel cell carcinoma (MCC). We investigated the RON signaling pathway in MCC. Fourteen cases of MCC were tested for the expression of RON and its ligand, MSP, using reverse transcription PCR (RT-PCR) and immunohistochemistry. The mutation of RON was also examined. RT-PCR identified transcription of both RON and MSP in all nine cases that were available for the examination. Immunohistochemistry showed the expression of RON (9/14 cases) and MSP (9/14 cases). Six cases out of 14 were positive for both RON and MSP. Normal Merkel cells were negative for RON and MSP expression. Missense mutation in the tyrosine kinase region of RON was detected in one of the 14 cases, and the case showed expression of RON. Transcription of RON and MSP was observed in MCC, and a considerable number of MCC cases expressed both RON and MSP, while Merkel cells do not express these molecules. The results suggest that RON signaling seems to play at least some role in the pathogenesis of MCC.
Copyright © 2011 Elsevier GmbH. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21723047     DOI: 10.1016/j.prp.2011.05.006

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  3 in total

Review 1.  Ron receptor tyrosine kinase signaling as a therapeutic target.

Authors:  Nancy M Benight; Susan E Waltz
Journal:  Expert Opin Ther Targets       Date:  2012-07-26       Impact factor: 6.902

Review 2.  Mutational analysis of merkel cell carcinoma.

Authors:  Derek J Erstad; James C Cusack
Journal:  Cancers (Basel)       Date:  2014-10-17       Impact factor: 6.639

3.  When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?

Authors:  Anne-Marie Baird; David Easty; Monika Jarzabek; Liam Shiels; Alex Soltermann; Sonja Klebe; Stéphane Raeppel; Lauren MacDonagh; Chengguang Wu; Kim Griggs; Michaela B Kirschner; Bryan Stanfill; Daisuke Nonaka; Chandra M Goparaju; Bruno Murer; Dean A Fennell; Dearbhaile M O'Donnell; Martin P Barr; Luciano Mutti; Glen Reid; Stephen Finn; Sinead Cuffe; Harvey I Pass; Isabelle Opitz; Annette T Byrne; Kenneth J O'Byrne; Steven G Gray
Journal:  Front Endocrinol (Lausanne)       Date:  2019-02-26       Impact factor: 5.555

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.